Discontinuation of pembrolizumab for advanced urothelial carcinoma without disease progression: Nati...
Discontinuation of pembrolizumab for advanced urothelial carcinoma without disease progression: Nationwide cohort study
About this item
Full title
Author / Creator
Publisher
United States: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Pembrolizumab, an anti‐programmed death 1 monoclonal antibody, has revolutionized the treatment of metastatic urothelial carcinoma. However, the optimal treatment duration for treatment responders has not been established. To address this, we retrospectively assess the treatment outcomes and duration of pembrolizumab for patients whose best respons...
Alternative Titles
Full title
Discontinuation of pembrolizumab for advanced urothelial carcinoma without disease progression: Nationwide cohort study
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_8233fb43169641d5938784ae9c87acbf
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_8233fb43169641d5938784ae9c87acbf
Other Identifiers
ISSN
2045-7634
E-ISSN
2045-7634
DOI
10.1002/cam4.5057
